Investigation of new agents in small-cell lung cancer

Research output: Contribution to journalArticlepeer-review


The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.

Original languageEnglish (US)
Pages (from-to)423S-426S
Issue number4 SUPPL.
StatePublished - 1993

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Investigation of new agents in small-cell lung cancer'. Together they form a unique fingerprint.

Cite this